glp-1 risks The promise and peril of agonists: What we do (and don't) know as of August 2024 risks of using glp 1

T., Sonne, N., Andreassen, K

This article explores the chemical properties of disulfide linkers, their mechanisms of action within ADCs, and the various payloads that can be utilized to enhance therapeutic outcomes in cancer treatment

KNOW THIS: Theyre not all FDA approved

Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing sp1 glycosylation

No published human clinical trial has studied this combination directly for any endpoint GH pharmacokinetics, safety, or performance outcomes

It can be either taken alone or in conjunction with other nutrients